Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug ...(er vaccines and other immunotherapeutic ...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
Date:2/11/2008
er vaccines and other immunotherapeutic products. Based in Frederick, MD, the company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune and anti-inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for the production of OncoVAX(R) vaccine.
http://www.vaccinogeninc.com
Contact:
Andrew L. Tussing
Vaccinogen
301-668-8400
'/>"/>
| SOURCE Vaccinogen Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:5/21/2008)...ark Laboratories, L.C., a,privately-owned biopharm...of enrollment into its Phase II clinical trial to ...n combination with standard of care therapy in,U.S... have previously,failed to respond to the standard...e company expects to announce interim data results...
(Date:5/21/2008)...oup of Leading Cancer Centers ...y 21 /- Endocare, Inc.,(Nas... focused on the,development of minimally invasive ... radiologists for tissue and tumor ablation, annou... method of freezing cancerous tumors,to destroy th...
(Date:5/20/2008)...positive results of nine month,PAINT trials for Dr...esults unveiled during plenary session of Eu...wswire/ -- Sahajanand Medical Technologies,Pvt. Lt...facturer of,drug-eluting stents, welcomed the posi...onths results of PAINT trial (PercutAneous INTerve...
(Date:5/20/2008)...igestive Disease Week -, CAMBRIDGE, Mass. and NEW...harmaceuticals, Inc. (formerly Microbia, Inc.) and...ounced the presentation of data,from a Phase 2b ra...ssessing the safety and efficacy of linaclotide in... of these data indicate that linaclotide met its,p...
Breaking Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 2Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 4Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 2Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 2Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 4Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 6Secondhand smoke increases teen test failure 1648 1Secondhand smoke increases teen test failure 1648 2Spectral partner launches EAA 28TM 29 Rapid Sepsis Diagnostic in Germany 711 1Spectral partner launches EAA 28TM 29 Rapid Sepsis Diagnostic in Germany 711 2Vical Licensee Sanofi aventis Initiates Phase 3 Trial to Reduce Amputations 336 1Vical Licensee Sanofi aventis Initiates Phase 3 Trial to Reduce Amputations 336 2Vical Licensee Sanofi aventis Initiates Phase 3 Trial to Reduce Amputations 336 3MedAire to Provide Medical Training for Bombardier Safety Standdown 1644 1MedAire to Provide Medical Training for Bombardier Safety Standdown 1644 2MedAire to Provide Medical Training for Bombardier Safety Standdown 1644 3[0] Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders[1] Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting[0] Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents[0] Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
...ylene Glycol,(DEG) Remains a Potential Health Haza...he U.S. Food and Drug,Administration (FDA) is warn...repackers, and health professionals who compound,m...hat glycerin, a,sweetener commonly used worldwide ...roducts, is not contaminated with diethylene,glyco...
...nnovations and a Health Conscious,Public?, WASHING... Food,and Drug Administration (FDA) must adapt to ...lthcare, Commissioner Andrew von,Eschenbach told a...,Annual Conference April 12 in Bethesda, Md. , FDA...ited,financial and personnel resources to deal wit...
Other Medicine Technology:FDA Advises Manufacturers to Test Glycerin for Possible,Contamination 2FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations,FDA Regulations 2(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3[0] Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008[0] The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders[0] InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008[0] Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
... survey, biting a bar of chocolate every day is co...h chocolates are high in fat and sugar, it has lon..., recent evidence suggests that, like other plant ...xidants, which can protect from chronic disease. ...
...tudy which suggests hormone suppression therapy co...ncer patient's chances of living free of the disea...y Hospital, examined the potential benefits of sup...e more commonly known male hormone testosterone, a...
... amount of fluids should be taken, in order to rep...er is far better than 'energy' drinks for keeping ...is maximum need for fluids,// henceforth, you'll b...ls topped up with regular drinks. There are a lot ...
...ch are protective substances, produced by the body...m kill the TB bacteria, researchers in the UK repo... journal Nature Medicine,// these heat-shock prote...body help cells survive stressful times and bolste...
Other Medicine News:Health News:Hormone Therapy applicable for Prostate Cancer 2The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety.
The 5500s electronic architecture incorporates advanced circuit designs optimized for efficiency and function. We call it HI VUE an engineering philosophy that directs the development of each subsys
The HI VISION 6500 high resolution digital ultrasound system offers advanced clinical imaging, enhanced operating efficiency, and remarkable clinical flexibility, all in robust and versatile configur
...features of the ELECTRA 1400C are designed to achi...away capabilities. This system includes automated ...nogen and factor assays in a single setup. It also...eparation of reference curves and patient sample d...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |